Sanofi partners with Biogen to expand accelRare rare-disease prediagnosis platform in France

Biogen Inc.

Biogen Inc.

BIIB

0.00
  • Sanofi added Biogen to accelRare, a free rare-disease pre-diagnosis platform co-developed with 13 French rare-disease networks, Medvir.
  • Biogen will promote accelRare to its healthcare network, targeting earlier suspicion of rare diseases such as Friedreich’s ataxia.
  • Partnership aims to expand the platform’s algorithm, prioritizing additional high-impact rare diseases where earlier diagnosis can change care.
  • accelRare, launched in 2024, targets more than 310 rare diseases, logged more than 7,000 pre-diagnoses, reported 4.54/5 physician satisfaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.